This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tankyrase TRF1-interacting ankyrin-related ADP-ribose polymerase (TNKS); TNKS2	*In vitro* and mouse studies identified a TNKS and TNKS2 dual inhibitor that could be useful for treating cancer. TNKS and TNKS2 regulate multiple cancer-associated pathways. *In vitro*, the lead molecule selectively inhibited TNKS and TNKS2 with IC_{50} values of 46 nM and 25 nM, respectively. In mice, the lead molecule showed good bioavailability following intraperitoneal and oral administration. Next steps include developing a strategy to stratify patients with cancer based on their expression of TNKS and TNKS2. *SciBX* **6**(14); doi:10.1038/scibx.2013.334 **Published online April 11, 2013**	Patent application filed covering composition of matter; licensing negotiations ongoing	Voronkov, A. *et al. J. Med. Chem.*; published online March 11, 2013; doi:10.1021/jm4000566 **Contact:** Stefan Krauss, Oslo University Hospital, Oslo, Norway e-mail: stefan.krauss@rr-research.no **Contact:** Jens P. Morth, same affiliation as above e-mail: j.p.morth@ncmm.uio.no **Contact:** Jo Waaler, same affiliation as above e-mail: jo.waaler@rr-research.no